Introduction
Toll-like receptors (TLR) are receptors of the innate immune system that recognize and bind to invading microbial pathogens through several so-called pathogenassociated molecular patterns.
1,2 TLR9 is located intracellularly and senses single-stranded DNA from microbial pathogens containing unmethylated CpG motifs, inducing thereby an adaptive immune response that is characterized by the production of inflammatory cytokines and interferons. TLR9 stimulates B cells and plasmacytoid dendritic cells to secrete a number of Th-1-promoting cytokines and chemokines, including IL-12, IL-6 and IFNs. [2] [3] [4] However, excessive activation of TLR9 can lead to chronic inflammation with serious consequences, such as those of systemic inflammatory response syndrome (SIRS), sepsis or autoimmune disorders, which, when occurring in the setting of allogeneic transplant, might be associated with a fatal outcome for patients. 5 TLR9s are able to sense variations in gene sequence and structure between microbial pathogens and host. Thereby, different DNA sequences, such as various CpG and non-CpG sequences, evoke different quantitative and qualitative immune responses. 6, 7 Further, besides the known role of TLR9 in the defense of microbial infections, TLR9 might also show some antitumor properties. In a number of preclinical trials, agonists of TLR9 have shown antitumor activity, alone and in combination with chemotherapy and radiotherapy, by enhancing an antibody-dependent cell-mediated cytotoxicity of mAbs. 8 Toll-like receptor 9 expression has been reported in T and B cells, including CD4 þ T cells and regulatory T cells, APCs, neutrophils, monocytes and epithelial cells. Furthermore, some studies suggest that TLR9 play an active role in the proliferation of activated CD4 þ T cells. [2] [3] [4] Other study groups report that their ligand has influence on the expansion and suppressive properties of regulatory T cells. 3 However, on binding to their specific ligands, TLR9 activate or regulate nuclear factor-kB, several kinases and immune-responsive genes by recruiting adaptor molecules to their intracellular signaling domain. 8 Recently, we and others have shown that gene variants of a number of innate immune receptors, such as NOD2 and TLR4, cytokines, such as IL10 and IL23R, or cytochrome P450 genes can influence considerably the outcome of allogeneic transplant. [9] [10] [11] [12] Therefore, we aimed in this study to investigate the possible influence of two known gene variants of TLR9 on the outcome of allogeneic transplant. Both gene variants, T1486C and T1273C, are characterized for their downregulation of TLR9 expression by luciferase reporter gene assays. 13 Further, the gene variant of T1273C was reported to be associated with asthma and atopic eczema. 14, 15 In this study, we observed in a retrospective study of a cohort of 293 patients, an influence of the homozygous C allele of T1486C on OS, TRM and relapse rate after transplant. These findings prompted us to start a prospective study for the same study end points in a second cohort of 120 patients with an observation period up to 12 months.
Patients and methods

Patients
The entire study population consisted of 413 transplant recipients and their HLA-identical donors who were transplanted at the University Hospital of Essen between October 1995 and March 2007. All patients received unmanipulated grafts containing T cells. The molecular analyses were performed without knowledge of the study end points of the analyzed patients. Pre-transplant histocompatibility testing of donors and patients generally consisted of low-resolution HLA-A, B, C-and highresolution HLA-DRB1, DQB1 DNA-based typing according to standard methods. 16 Inclusion criteria were the availability of pre-transplant blood samples and the willingness of the patients to participate in the study. Conditioning regimens had been published earlier. 17 The study consists of two parts and included two separate cohorts. We used the initial cohort to screen for an association between TRM and polymorphism in TLR genes. The second cohort included 120 recipients with their HLA-identical donor and was performed prospectively. There were significant differences between these groups in donor age, sex constellation between recipient and donor, disease stage and conditioning with TBI (Table 1) . A final analysis of clinical end points included both cohorts. All patients and donors gave their written informed consent according to the protocols approved by the Institutional Review Board on Medical Ethics at the University Hospital of Essen.
Isolation of genomic DNA DNA was prepared from PBMC obtained from the donor and patient before the transplant using the phenol/chloroform method. 18 Genotyping of SNP Genotyping for TLR-9 was analyzed by a Lightcycler (Roche Diagnostics, Mannheim, Germany) protocol using the hybridization probes and primers published by Hamann et al. 19 The primers for the PCR were synthesized by MWG Biotech (Ebersberg, Germany). The fluorescencelabeled sensor and anchor hybridization probes for the Lightcycler protocol were purchased from TIB MOLBIOL (Berlin, Germany). The sensor probes cover the SNP and exhibit a different melting temperature dependent on the binding to the wild-type or variant allele. The anchor probes were designed to display a significantly higher melting temperature compared with the corresponding sensor probes. PCR and subsequent melting curve analysis were performed using the Lightcycler device and software. Control samples confirmed by sequencing were included in each run.
Leukemia cell lines
The following cell lines were used: K562, CML in myeloid blast crises; HEL, human erythroleukemia (FAB M6) with hypotriploid karyotype and 2.3%. polyploidy, OPM-2 and RPMI 2886, both myeloma cell lines. All cell lines were purchased from DSMZ, (Braunschweig, Germany). Cells were grown in RPMI 1640 medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal bovine serum as described. 18 All cells were maintained in a humidified incubator at 37 1C with 5% CO2.
RNA isolation, real-time reverse transcription PCR, CpG-rich oligonucleotides (ODNs) RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Real-time reverse transcription PCR was performed as published earlier for bcr-abl and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) real-time reverse transcriptase PCR. 20 The following primers and hybridization probes were used for TLR9: primers 5 0 -ACC TCA AAC GAG AGC C-3 0 and 5 0 -AGA GGA CTG CCG TAC A-3 0 , hybridization probes 5 0 CCA CTG TCC GAC TCA CCC-Fl and LC Red640-ATT CTA CAA GCC TAG CTT CTC CTG G-PH. For MYD88 and JAK-2, we used primers and probes as published earlier. 21, 22 Primer and hybridization probes for real-time PCR for bcr-abl and GAPDH were published previously. 20 Quantification of RNA transcript expression was normalized determining the ratio between expression levels of targets and GAPDH. CpG-rich ODNs and control ODNs were used as described earlier. 4 Quantitation of peripheral blood cell subsets Peripheral blood cell subsets were determined by flow cytometry as described earlier. 23 Cell proliferation assay Cell proliferation was determined by 5-bromo-2-deoxyuridine (BrdU) incorporation using the Roche Kit (Mannheim, Germany) following the manufacturer's instructions.
Statistical Analysis
Acute GVHD and chronic GVHD were diagnosed and graded according to the standard criteria. 24, 25 Death in remission was defined as any death occurring before the recurrence of the underlying disease. The cumulative rates of incidence of acute GVHD, chronic GVHD, and death in remission and OS were calculated with the use of the Kaplan-Meier method. 26 Differences between time-toevent distribution functions were compared by using logrank test (Mantel-Haenszel). 27 A stepwise proportional hazards general linear model analysis was used to evaluate interactions of different covariates on the analytical end point of TRM and rate of relapse. Covariates in proportional hazards general linear model analyses were stratified according to severe acute GVHD (only for the end point TRM), age (o40 or 440 years), gender constellation (male patient with female donor or other), CC homozygous C allele of TLR9 gene at 1486 vs TC or TT alleles, sibling donor vs unrelated donor, graft-type (PBSC or BM), disease stage (advanced vs early disease stage) and HLAidentical vs mismatch were analyzed. Conditional risk ratios (RRs) and their 95% confidence intervals (CIs) were derived from proportional hazards general linear model analyses after adjustment for significant covariates in the model. Any variable associated with a hazard ratio of 2.0 or more or 0.5 or less, or a P-value for trend of 0.05 or less in the first cohort was reevaluated in the second cohort.
The demographic characteristics of the groups were compared by means of descriptive methods, and significant differences were identified by means of Fisher's exact test. Statistical analysis was performed using the SPSS software version 13.0. Only patients surviving more than 30 days were included in the analysis of acute GVHD. A minimum of 100 days of follow-up was the criteria for chronic GVHD.
Results
First cohort
In the first cohort of 293 recipients/donor pairs, a homozygous CC allele gene variant of TLR9 at position -1486 occurred with a frequency of 18.1% in recipients and 18.8% in donors. Patients with the CC alleles had significantly lower 5-year estimates for death in remission with 11.7% þ 5.0% compared with 36.4% of patients with TT or TC alleles (Po0.003). In addition, the 5-year estimate for rate of relapse was lower at 13.2% þ 6.3% compared with 33.3% þ 4.3% in patients with TC or TT alleles of -1486 (Po0.007). The lower rate of relapse and the lower estimate for death in remission resulted consequently in an improved 5-year OS with an estimate of 86.1% þ 5.3% compared with only 48.3% þ 4.0% of patients with TC or CC alleles. However, we did not find any statistical meaningful differences in the incidences of acute grade 2-4 GVHD (58.33 vs 60.4%) or severe acute GVHD grade 3-4 (22.9 vs 22.75%) between both study groups.
Patients transplanted from donors with CC allele at position -1486 of TLR9 had a slightly improved estimate of 5-year OS of 56.8% compared with 47.9% (Po0.18) for patients with donors with TC or TT alleles, which was statistically not significant. Further, no differences were found in patients transplanted from donors with CC allele in the estimates for TRM and rate of relapse (data not shown).
Only seven patients (2.5%) in cohort 1 had a homozygous C allele of the TLR9 gene variant at position 1237. In addition, only 10 patients (3.5%) were transplanted from donors with a homozygous C allele at 1237. The numbers were too low to see statistically significant differences in TRM, relapse rate or OS between the groups. Nevertheless, it was remarkable that none of the seven patients with the CC alleles had a severe GVHD (0 vs 21.5%, Po0.19, not significant).
Second cohort
In the second cohort with 120 patients, 20% of the recipients and 21% of the donors had the homozygous Improved survival in patients with TLR-9 gene polymorphisms after transplant AH Elmaagacli et al CC allele of the TLR9 gene at position 1486. As found in cohorts1 and 2, recipients with the CC alleles had improved calculated estimates for TRM, relapse rate and OS. The estimate of 1-year TRM was 10.0% þ 6.8% vs 29.4% for patients with TC or CC alleles (Po0.09). The 1-year estimate of OS was 90.0% þ 6.8% vs only 53.5% of recipients with TC or TT alleles (Po0.028). In addition, the rate of relapse was lower with an estimate of 5.6% þ 5.4% vs 34.1% þ 7.6% (Po0.046). No differences were seen in the incidence of acute GVHD grades 2-4 (65.2 vs 57.9%) or severe acute GVHD grades 3-4 (21.7 vs 23.4%) as already found in cohort 1.
Both cohorts
Thereafter, we analyzed the results of both cohorts together for TRM, relapse and OS. The results are shown in Figure  1-4 . As expected, a significantly improved relapse rate, TRM and OS were seen for recipients with the homozygous CC allele of TLR9 at position 1486.
The consistency of the effects between the two independent cohorts suggest that the TLR9 1486 CC genotype was associated with a better outcome after transplant.
Multivariate analysis for death in remission and risk for relapse For TRM and risk of relapse, acute GVHD grades 3-4, age (o40 or 440 years), gender constellation (male patient with female donor, or other), CC-allele of TLR9 at position 1486 at recipient's side vs others, sibling donor vs unrelated donor, graft-type (PBSC or BM), HLA mismatch between donor and recipient, and disease stage (advanced vs early disease stage) were analyzed. According to this multivariate analysis, the gene variant with the CC alleles at 1486 of TLR9 reduced the risk for TRM (RR 0.35, 0.016-0.78; (95% CI); Po0.011), whereas the risk for TRM increased by the occurrence of severe acute GVHD (RR: 3.1, 1.9-4.9; (95% CI); Po0.0001), age over 40 years (RR: 1.8, 1.1-2.9; (95% CI); Po0.011), HLA mismatch between donor and recipient (RR: 2.7, 1.6-4.4; (95% CI); Po0.001) and disease stage (RR: 2.5, 1.5-4.2; (95% CI); Po0.0001) after transplant.
Immune reconstitution 3, 6 and 12 months post transplant The numbers of peripheral blood CD4 þ T cells and CD8 þ CD4 þ T cells were lower 3, 6 and 12 months after transplant in patients with the CC allele (n ¼ 12) compared with patients with the wild-type T allele (n ¼ 42; Table 2 ). A slower cellular reconstitution after transplant with a lower number of cells was also seen for CD19 þ B cells, natural killer cells, T reg cells in patients with the CC alleles, but these differences did not reach significance level (Table 2) owing to the low number of patients.
TLR9 expression in recipients with CC alleles of TLR9 gene at 1486
As the CC allele variant at -1486 is associated with the down-regulation of TLR9 expression by reporter gene assay, we analyzed in cohort two 16 recipients with CC allele and 24 recipients with TT allele before transplant for their TLR9 mRNA expression in mononuclear cells of peripheral blood. We found a decreased TLR9 mRNA expression in recipients with CC allele (2099 TLR9/ GAPDH quotient) vs 3044 (TLR9/GAPDH quotient), but the difference was not significant (Po0.11) as shown in Figure 2b . Non-CpG ODNs were also able to increase the expression of TLR9 and MYD88 to a lesser extent. Further, we observed a reduction in MRD of HEL and K562 and an increase in the proliferation rate of OPM2 and RMPI. All data are shown in Figure 4 .
Discussion
Here, we report that a gene variant of TLR9 with a homozygous C allele at position 1486 strongly improves the outcome of patients who underwent allogeneic transplant by reducing threefold times the rate of TRM and furthermore, to a lesser extent, the rate of relapse. OS increased up to 83% compared with 46% in patients with the wild-type gene variant. The results are based on a two cohort analyses consisting of a retrospective analysis of the first cohort, and thereafter a prospectively performed analysis of a second smaller cohort with a shorter observation period. Multivariate analyses confirmed that besides other commonly known factors as age of patients, disease stage, occurrence of severe acute GVHD and HLAmismatches between donor and recipient, the CC gene variant at position 1486 of TLR9 had a significant influence on the occurrence of TRM and the relapse rate after transplant.
It is known that immunosuppressive therapies for prophylaxis or treatment of GHVD and a slow immune reconstitution of the graft facilitate the occurrence of lifetreating opportunistic infections as fungal infections or CMV infections in patients after transplant. 23 Consequently, almost all transplanted patients are challenged The number of peripheral blood CD3+CD4+ T cells and CD8+CD4+ T cells were lower 3, 6 and 12 months after transplant in patients with the CC allele (n ¼ 12) compared with patients with the wild-type T allele (n ¼ 42).
with often recurring, more or less severe infections. Thereby, they are often confronted with TLR9-activating CpG-rich DNA sequences from microbial invaders. In addition, non-CpG-containing DNA sequences originating from apoptotic cells after conditioning regimen or after GVHD reactions could frequently induce the activation of TLR9. Consequently, TLR9 seems to be often involved in many immune responses arising at several occasions throughout the whole post-transplant period, as it is reported for its involvement in the progression of autoimmune disease as systemic lupus erythematosus, for example, which is also a different kind of overwhelming immune response.
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So we do hypothesize that TLR9-based immune responses in the defense of microbial infections are not always occurring within an appropriate manner after transplant. Recent reports show that CpG-rich ODNs are able to induce through TLR9 SIRS and sepsis. 5 Overwhelming immune responses, such as these are potentially dangerous for patients after transplant, because they bear the risk to kill patients, as SIRS and sepsis do not occur uncommonly in transplanted patients. These arguments are endorsed by TLR9 knockout mice transplant experiments. Studies using C57BL/6 knockout mice showed that TLR9-/-recipients of grafts had an improved survival and reduced GVHD after transplant compared with TLR9 þ / þ mice. The observed reduced mortality and morbidity in TLR9-/-mice were related to reduced stimulatory activity of TLR9-/-spleen APCs after conditioning and reduced proliferation of allogeneic donor T cells. 28 The gene variant with the homozygous C alleles at 1486 is associated with a reduced TLR9 gene expression as reported earlier by Tao et al. 13 Concordantly, we also found a 33% reduction of TLR9 mRNA expression in mononuclear cells from the peripheral blood of patients with the CC alleles compared with patients with the wildtype gene. Further, TLR9 is reported to have influence on the activation and proliferation of CD4 þ T cells, CD4 þ CD25 þ T reg and B cells. 3 Indeed, we found that the cellular immune reconstitution for CD4 þ T-helper cells and CD3 þ CD8 þ cytotoxic T cells at three different time points after transplant was slower in patients with CC alleles at 1486 compared with patients with the wild-type gene at 1486. The mean numbers of T-helper cells of the patients with the wild-type alleles of 1486 remained in the field of those that we reported earlier from patients after transplant, 17, 23 whereas the mean numbers of T-helper cells of patients with the CC alleles at 1486 were up to one-third lower after transplant. However, the mean number of T cells remained higher than that of those patients who underwent T-cell-depleted transplantation, and was higher than the absolute number of 100 T-helper cells/ml, which is associated as critical for the occurrence of severe opportunistic infections as CMV infections. 29 The lower TLR9 expression and the slower cellular immune reconstitution of patients with CC alleles at 1486 strongly supports our hypothesis that these patients do not have the tendency for overwhelming immune reactions as SIRS or sepsis. Another reason for a moderate immune response in patients with CC alleles of 1486 might be caused by the role of TLR9 ligands on the activity of CD þ CD24 þ T reg cells. So it is reported that ligands of TLR9 partially abrogate the suppressive activity mediated by regulatory CD4 þ CD25 þ T cells. 3 The loss of suppression is in part due to the direct effect of TLR9 ligands on effector T cells. Reduced TLR9 expression as found in the genetic variant of -1486 causes a less extend of suppressive activity on regulatory CD4 þ CD25 þ T cells, which, for example, might play a role in the immune response of transplanted patients to infections.
More difficult to explain is the lower rate of relapse in patients with the genetic variant of TLR9 seen in this study. However, to test whether TLR9 ligands do have antitumour features, we used the HEL cell line, which has CC alleles at 1486, and compared the results with those obtained from the K562 cell line with the wild-type allele at 1486. The application of CpG-rich ODNs in K562 and HEL cell lines induced a moderate increase of TLR9 expression, whereas the MYD88 expression increased significantly only in K562 cell lines. However, we found that the leukemic-specific expression of disease-specific transcripts (bcr-abl in K562 and JAK2 in HEL) decreased in both cell lines when CpG ODNs or non-CpG-containing ODNs were applied, showing that these antileukemic effects may probably not mainly involve the MYD88 gene signaling pathway.
Blazar et al. 30 reported that CpG-rich ODNs do have antileukemic effects in ALL and AML. 31 They postulated that the antileukemic effect of CpG-rich ODNs depended on natural killer cells rather than T or B cells in transplant recipients using T-cell depleted transplant models. Further, they found that donor lymphocyte infusions combined with CpG-rich ODNs unfold a synergistic effect in mice experiments. 29 However, our results also do suppose a direct influence of ODNs on leukemic cells without the effect of natural killer cells, B cells, CD4 þ T-helper cells or CD3 þ CD8 þ T-cytotoxic cells, as reported earlier by some study groups. Further, we evaluated two multiple myeloma cell lines for their response to ODNs. After stimulation with CpG ODNs and non-CpG-containing ODNs, we found an increase of TLR9 and MYD88 gene expressions in both multiple myeloma cell lines. RPMI 8226 was genotyped as wild type for 1486, whereas OPM-2 had the genetic variant of TLR9. In addition, no really different immune responses were observed between both the cell lines, which could explain the improved relapse rate.
Our present data suggest a major role of TLR 9 in patients who underwent an allogeneic transplantation. Therefore, we suggest the genotyping of TLR9 1486, because it might be an independent and strong marker for outcome of transplant, and could be used as a prognostic factor in patients planning a transplant.
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